Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Untersuchung von Patritumab Deruxtcan plus Pembrolizumab mit anderen Antikrebs-Wirkstoffen in Teilnehmern mit Hochrisiko im Frühstadium Triple-Negative oder Hormonrezeptor-Tiefe positive/HER-2-negative Brustkrebs (MK-1022-010, Herthaa-Breast-03)

11. November 2026 aktualisiert von: Merck Sharp & Dohme LLC

Eine randomisierte Phase-2-Studie mit offenem Label zur Bewertung der Sicherheit und Wirksamkeit von Patritumab Deruxtcan plus Pembrolizumab, das entweder vor oder nach Carboplatin/Paclitaxel plus Pembrolizumab im Vergleich zu Pembrolizumab in Kombination mit Chemotherapie und adjuvantem Pembrolizumab-Triple-Triple-Triple-Triple-Triple-Triple-Triple-Tri-Stufe-Triple-Tri-Stufe verabreicht wurde Negativer oder hormonrezeptor-niedriger positiver/menschlicher epidermaler Wachstumsfaktor-Rezeptor-2 Negativer Brustkrebs (Hertena-Breast03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

372

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Córdoba, Spanien, 14004
        • Rekrutierung
        • Hospital Universitario Reina Sofia ( Site 1702)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34 957012408
    • Catalonia
      • Badalona, Catalonia, Spanien, 08916
        • Rekrutierung
        • Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34934978925
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spanien, 28027
        • Rekrutierung
        • Clinica Universidad de Navarra ( Site 1703)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +34913531920
      • Seoul, Südkorea, 03080
        • Rekrutierung
        • Seoul National University Hospital ( Site 2400)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82220720850
      • Seoul, Südkorea, 05505
        • Rekrutierung
        • Asan Medical Center ( Site 2401)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82230103217
      • Seoul, Südkorea, 03722
        • Rekrutierung
        • Severance Hospital, Yonsei University Health System ( Site 2402)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82222288135
      • Taichung, Taiwan, 407
        • Rekrutierung
        • Taichung Veterans General Hospital ( Site 2502)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +886423592525
      • Tainan, Taiwan, 704
        • Rekrutierung
        • National Cheng Kung University Hospital ( Site 2503)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +88662353535
      • Taipei, Taiwan, 112
        • Rekrutierung
        • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 886228970011x1686
    • California
      • Santa Monica, California, Vereinigte Staaten, 90404
        • Rekrutierung
        • UCLA Hematology/Oncology - Parkside ( Site 0021)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 424-402-9520
    • Illinois
      • Skokie, Illinois, Vereinigte Staaten, 60077
        • Rekrutierung
        • Orchard Healthcare Research Inc. ( Site 0006)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 847-568-9932
    • Montana
      • Billings, Montana, Vereinigte Staaten, 59102
        • Rekrutierung
        • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 406-238-6685
    • Oregon
      • Happy Valley, Oregon, Vereinigte Staaten, 97015
        • Rekrutierung
        • Northwest Cancer Specialists, P.C. ( Site 8003)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 360-944-9889
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Rekrutierung
        • SCRI Oncology Partners ( Site 7000)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 844-482-4812
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75246
        • Rekrutierung
        • Texas Oncology - DFW ( Site 8000)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 214-370-1067
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • Houston Methodist Hospital ( Site 0022)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 713-441-9948
    • Virginia
      • Norfolk, Virginia, Vereinigte Staaten, 23502
        • Rekrutierung
        • Virginia Oncology Associates (VOA) ( Site 8001)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 844-482-4812

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
  • Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
  • Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
  • Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled or significant cardiovascular disease before randomization
  • Has any history of or evidence of any current leptomeningeal carcinomatosis.
  • Has clinically significant corneal disease
  • Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
  • Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
  • Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
  • Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has concurrent active HBV and HCV infection
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Andere Namen:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • PARAPLATIN®
Experimental: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Andere Namen:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • PARAPLATIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • ADRIAMYCIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Andere Namen:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Andere Namen:
  • LYNPARZA®
Experimental: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Andere Namen:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • PARAPLATIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • ADRIAMYCIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Andere Namen:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Andere Namen:
  • LYNPARZA®
Aktiver Komparator: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Andere Namen:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Andere Namen:
  • PARAPLATIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • ADRIAMYCIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Andere Namen:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Andere Namen:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Andere Namen:
  • LYNPARZA®

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Zeitfenster: Up to ~43 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1.

Up to ~43 weeks
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Zeitfenster: Up to 21 days

A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.

Up to 21 days
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Zeitfenster: Up to ~30 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1.

Up to ~30 weeks
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Zeitfenster: Up to ~30 weeks

pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Number of Participants Experiencing an AE
Zeitfenster: Up to ~103 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2.

Up to ~103 weeks
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Zeitfenster: Up to ~90 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2.

Up to ~90 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Zeitfenster: Up to ~30 weeks

pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Event-Free Survival (EFS)
Zeitfenster: Up to ~100 months

EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Overall Survival (OS)
Zeitfenster: Up to ~100 months

OS is defined as the time from randomization to date of death due to any cause.

Up to ~100 months
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Zeitfenster: Up to ~100 months

DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Residual Cancer Burden (RCB)
Zeitfenster: Up to ~30 weeks

RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28).

Up to ~30 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Studienleiter: Medical Director, Merck Sharp & Dohme LLC

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. März 2025

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

16. März 2031

Studienanmeldedaten

Zuerst eingereicht

21. Januar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Januar 2025

Zuerst gepostet (Tatsächlich)

28. Januar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren